Cutler Group LP Ionis Pharmaceuticals Inc Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$31.71 - $43.0 $91,959 - $124,700	-2,900 Reduced 96.67%	100 $3,000
Q1 2022 Apr 14, 2022	SELL	$29.88 - $37.04 $38,545 - $47,781	-1,290 Reduced 30.07%	3,000 $111,000
Q4 2021 Jan 18, 2022	BUY	$25.61 - $35.1 $89,378 - $122,499	3,490 Added 436.25%	4,290 $130,000
Q2 2021 Jul 19, 2021	BUY	$34.54 - $47.25 $24,178 - $33,075	700 Added 700.0%	800 $31,000
Q4 2018 Feb 05, 2019	SELL	$43.37 - $59.54 $21,685 - $29,770	-500 Reduced 83.33%	100 $5,000
Q3 2018 Nov 07, 2018	BUY	$42.88 - $53.7 $11,577 - $14,499	270 Added 81.82%	600 $30,000
Q2 2018 Aug 10, 2018	BUY	$40.53 - $50.7 $9,321 - $11,661	230 Added 230.0%	330 $13,000
Q1 2018 May 11, 2018	SELL	$44.08 - $55.05 $436,259 - $544,829	-9,897 Reduced 99.0%	100 $4,000
Q4 2017 Jan 17, 2018	SELL	$50.3 - $64.39 $329,163 - $421,368	-6,544 Reduced 39.56%	9,997 $502,000
Q3 2017 Oct 17, 2017	BUY	$45.56 - $59.57 $753,607 - $985,347	16,541	16,541 $838,000

402

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.16B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.